Abstract: Provided are pharmaceutical compositions useful for the treatment and/or prevention of a disorder, such as addiction. For example, pharmaceutical compositions are provided that comprise a first active pharmaceutical component (e.g., metyrapone) and a second active pharmaceutical component (e.g., oxazepam). The compositions may be constructed in such a manner as to limit the physical contact between the first and second active pharmaceutical components, thus preventing any degradation of the active pharmaceutical components resulting form interaction between the two components. The compositions may include at least one pharmaceutically acceptable excipient. Also provided are methods of making the compositions as well as kits containing materials to provide the compositions.

Abstract: Provided are pharmaceutical compositions useful for the treatment and/or prevention of a disorder, such as addiction. For example, pharmaceutical compositions are provided that comprise a first active pharmaceutical component (e.g., metyrapone) and a second active pharmaceutical component (e.g., oxazepam). The compositions may be constructed in such a manner as to limit the physical contact between the first and second active pharmaceutical components, thus preventing any degradation of the active pharmaceutical components resulting form interaction between the two components. The compositions may include at least one pharmaceutically acceptable excipient. Also provided are methods of making the compositions as well as kits containing materials to provide the compositions.

Abstract: An orally administrable solid dosage form containing a compacted ribavirin composition having an advantageously high tap density of at least 0.6 g/mL as well as surprisingly rapid disintegration and dissolution rates and wherein the ribavirin is substantially free of polymorphic forms of ribavirin and a process for making such solid dosage forms are disclosed.

Abstract: An orally administrable solid dosage form containing a compacted ribavirin composition having an advantageously high tap density of at least 0.6 g/mL as well as surprisingly rapid disintegration and dissolution rates and wherein the ribavirin is substantially free of polymorphic forms of ribavirin is disclosed.

Abstract: An orally administrable solid dosage form containing a compacted ribavirin composition having an advantageously high tap density of at least 0.6 g/mL as well as surprisingly rapid disintegration and dissolution rates and wherein the ribavirin is subsantially free of polymorphic forms of ribavirin is disclosed.

Abstract: A pharmaceutical composition in the form of a substantially amorphous solid solution comprising an antifungal compound of the formula I: ##STR1## wherein: X is F; and R.sub.1 is ##STR2## or an ester or ether of said compound of Formula I; and a soluble or insoluble polymer such as: povidone or crospovidone, wherein the ratio of said compound to said polymer is about 1:3 to about 1:6 is disclosed.

Abstract: A process of making an orally administrable solid dosage form containing a compacted ribavirin composition having an advantageously high tap density of at least 0.6 g/mL as well as surprisingly rapid disintegration and dissolution rates and wherein the ribavirin is substantially free of polymorphic forms of ribavirin as determined is disclosed.

Abstract: An orally administrable solid dosage form containing a compacted ribavirin composition having an advantageously high tap density of at least 0.6 g/mL as well as surprisingly rapid disintegration and dissolution rates and wherein the ribavirin is substantially free of polymorphic forms of ribavirin is disclosed.

Abstract: A pharmaceutical composition comprising:i) substantially inert beads; wherein said beads are coated withii) an antifungal agent which is (-)-(2R-cis)-4-?4-?4-?4-??-5-(2,4-difluorophenyl)tetrahydro-5-(1H-1,2,4-tr iazol-1-ylmethyl)furan-3-yl!methoxy!phenyl!-1-piperazinyl!phenyl!-2,4-dihyd ro-2-?(S)-1-ethyl-2(S)-hydroxypropyl!-3H-1,2,4-triazol-3-one;iii) a binder to enables the antifungal compound to adhere to said beads.The composition enables the antifungal compound, which has very low water solubility, to have enhanced bioavailability in mammals, such as humans.

Abstract: A pharmaceutical composition comprising:i) an antifungal agent which is (-)-(2R-cis)-4-?4-?4-?4-??-5-(2,4-difluorophenyl)-tetrahydro-5-(1H-1,2,4-t riazol-1-ylmethyl)furan-3-yl!methoxy!phenyl!-1-piperazinyl!phenyl!-2,4-dihy dro-2-?(S)-1-ethyl-2(S)-hydroxypropyl!-3H-1,2,4-triazol-3-one;ii) at least one non-ionic surfactant; andiii) a diluent.The composition enables the antifungal compound, which has very low water solubility, to have enhanced bioavailability in mammals, such as humans.

Abstract: Pharmaceutical compositions for use in the treatment of cough/cold symptoms comprising loratadine, ibuprofen and pseudoephedrine are disclosed.

Abstract: A long acting diltiazem formulation is disclosed that comprises more than 35 percent by weight of a swellable hydrophilic polymer.Release rate is also controlled by the application of diffusion controlled membrane to the matrix tablet containing swellable hydrophilic polymers. The diffusion rate through the membrane depends upon the composition or ratio of hydrophilic to hydrophobic coating agent.

Abstract: An immediate release diltiazem tablet is disclosed that exhibits an unexpectedly rapid bioavailability profile when the active ingredient is diltiazem.

Abstract: Pharmaceutical compositions for use in the treatment of cough/cold symptoms comprising loratadine, ibuprofen and pseudoephedrine are disclosed.

Abstract: A sustained release dosage form of labetalol hydrochloride is disclosed comprising the active ingredient in a polymeric matrix of hydroxypropylmethylcellulose and polyvinylpyrrolidone and a pharmaceutically acceptable organic acid.

Abstract: The invention relates to a controlled release dosage form comprising three actives: acetaminophen, pseudoephedrine and dexbrompheniramine.

Abstract: Controlled release solid dosage forms comprising less than about one-third of the total dosage form weight of hydroxypropylmethylcellulose USP 2910 are disclosed.

Abstract: The invention relates to a controlled release dosage form comprising three actives: acetaminophen, pseudoephedrine sulfate and dexbrompheniramine maleate.

Abstract: The invention relates to a controlled release dosage form comprising three actives: acetaminophen, psueudoephedrine sulfate and dexbrompheniramine maleate.